Literature DB >> 3926886

Characterization and partial purification of a specific interleukin 2 inhibitor.

M Honda, C Chan, E M Shevach.   

Abstract

To investigate the mechanisms that regulate the action of interleukin 2 (IL 2) and possibly limit its activity, we screened supernatants of mouse spleen cell cultures which had been stimulated with concanavalin A (Con A) for their ability to inhibit IL 2-mediated proliferation of a cloned IL 2-dependent line. Inhibitory activities with m.w. of 10,000 to 12,000 and 60,000 to 80,000 daltons could be identified in supernatants of both L3T4+ and Ly-2+ T cells, but not in supernatants of Con A or lipopolysaccharide-stimulated B cells. Maximal inhibitory activity was observed after 3 to 4 days of stimulation, and this inhibitory activity could be overcome by increasing the stimulatory concentration of IL 2. When the factor was further purified by reverse-phase high pressure liquid chromatography, it eluted as a single peak with an m.w. of 11,000 to 12,000 daltons which inhibited IL 2- but not IL 3-dependent proliferation. The mechanisms by which this new lymphokine might play in the control of the clonal expansion of T lymphocytes are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926886

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Induction of activated killer cells from human lymphocytes by medullasin (a serine protease in bone marrow cells).

Authors:  Y Aoki; T Hase; K Oshimi; K Suzuki
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

2.  Normal mitogen-induced suppression of the interleukin-6 (IL-6) response and its deficiency in systemic lupus erythematosus.

Authors:  R J Warrington; W J Rutherford
Journal:  J Clin Immunol       Date:  1990-01       Impact factor: 8.317

3.  Identification of a histamine release inhibitory factor produced by human mononuclear cells in vitro.

Authors:  R Alam; J A Grant; M A Lett-Brown
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

4.  Apparent interleukin 2 (IL-2) inhibitory activity of human serum is due to rapid killing of IL-2-dependent mouse cells.

Authors:  S B Pruett; A Lackey
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

5.  Immunotherapy of collagen-induced arthritis by a T-cell antiproliferative molecule.

Authors:  D J Spannaus-Martin; R Holmdahl; T F Kresina
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

6.  Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders.

Authors:  J Y Djeu; T Kasahara; J E Balow; G C Tsokos
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

7.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  Keratinocyte-derived T-cell growth factor: a T-cell growth factor functionally distinct from interleukin 2.

Authors:  T S Kupper; D L Coleman; J McGuire; D Goldminz; M C Horowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

9.  Protective immunity in toxoplasmosis: correlation between antibody response, brain cyst formation, T-cell activation, and survival in normal and B-cell-deficient mice bearing the H-2k haplotype.

Authors:  V Brinkmann; J S Remington; S D Sharma
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

10.  Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats.

Authors:  J Zielasek; V Burkart; P Naylor; A Goldstein; U Kiesel; H Kolb
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.